BMXMF (BioMerieux) Long-Term Debt: $247 Mil (As of Dec. 2025)


BMXMF BioMerieux SA BMXMF
67 GF Score
Price $82.78
GF Value $127.88
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Long-Term Debt?

BioMerieux BMXMF 67 Long-Term Debt is $247 Mil as of Dec. 2025. GuruFocus rates BMXMF with a GF Score™ of 67/100 and a GF Value™ of $127.88 (Significantly Undervalued). The stock has 3 warning signs investors should review.

BioMerieux's Long-Term Debt for the quarter that ended in Dec. 2025 was $247 Mil.

BioMerieux's quarterly Long-Term Debt increased from Dec. 2024 ($217 Mil) to Jun. 2025 ($245 Mil) and increased from Jun. 2025 ($245 Mil) to Dec. 2025 ($247 Mil).

BioMerieux's annual Long-Term Debt declined from Dec. 2023 ($255 Mil) to Dec. 2024 ($217 Mil) but then increased from Dec. 2024 ($217 Mil) to Dec. 2025 ($247 Mil).

BioMerieux  (OTCPK:BMXMF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

BioMerieux Long-Term Debt Related Terms

BioMerieux Long-Term Debt Historical Data

* Premium members only.

The historical data trend for BioMerieux's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMerieux Long-Term Debt Chart

BioMerieux Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 299.66 238.14 255.29 216.86 247.42

BioMerieux Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 255.29 255.33 216.86 245.44 247.42
BMXMF
67GF Score
BioMerieux SA BMXMF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $247 Mil mean?
BioMerieux (BMXMF) has a Long-Term Debt of $247 Mil as of Dec. 2025.
Is BioMerieux's Long-Term Debt too high?
BioMerieux's current Long-Term Debt is $247 Mil. Overall, BioMerieux has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's Long-Term Debt compare to TMO and DHR?
BioMerieux's Long-Term Debt of $247 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. BioMerieux's current Long-Term Debt is $247 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (BMXMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $127.88, compared to a current price of $82.78 — trading 35.3% below its estimated fair value. The current Long-Term Debt is $247 Mil. BioMerieux's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For BioMerieux (BMXMF), the current Long-Term Debt is $247 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMerieux (BMXMF) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of $82.78 is trading 35.3% below its estimated GF Value™ of $127.88. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for BMXMF:

  • Long-Term Debt: $247 Mil
  • GF Value™: $127.88 vs. price of $82.78 (35.3% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the BMXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
67GF Score

Get the complete analysis for BMXMF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$82.78
Price
$127.88
GF Value